Back to News
Market Impact: 0.15
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Source: globenewswire.com
Healthcare & BiotechProduct Launches
A presentation will introduce ART26.12, described as the first selective FABP5 inhibitor to enter human clinical studies, at the world's largest gathering of pain professionals. The article provides no clinical results or additional trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Apple responds to user reports of broken iPhone Duo screens on new foldable phone
- Uh oh, it sounds like the iPhone Duo keeps cracking and users aren’t happy about it
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Apple stock has become an anti-AI trade. Here’s why